Full Press Release Details
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors.
IDYA
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
Key Takeaway: IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors